LONDON - Cambridge Cognition Holdings (LON:COGC) PLC (AIM: COG), a developer of brain health assessment software, has acknowledged the role of its CANTAB cognitive assessment tool in supporting the recent FDA approval of Bristol Myers (NYSE:BMY) Squibb's schizophrenia treatment, Cobenfy. The drug, a novel therapy targeting M1 and M4 muscarinic receptors, marks a significant development in the treatment of schizophrenia.
Cobenfy, which is based on the compounds Xanomeline and Trospium, is the first new schizophrenia medication approved in several decades and is noted for its effectiveness in reducing both the positive and negative symptoms associated with the condition. This is a departure from traditional antipsychotic treatments that primarily block dopamine receptors.
The use of CANTAB, which delivers precise and objective cognitive function measurements in clinical trials, was instrumental in a post-hoc analysis of two Phase 3 trials. The results, published in The American Journal of Psychiatry, demonstrated cognitive performance improvements in patients with acute schizophrenia after treatment with Cobenfy.
Cambridge Cognition has expressed that these findings underscore the efficacy of CANTAB in tracking cognitive improvements, which is crucial in the development of new treatments for schizophrenia. The company remains dedicated to supporting pharmaceutical research through its digital assessment technologies.
Rob Baker, Chief Operating Officer and Joint Managing Director at Cambridge Cognition, stated that the success of Cobenfy in clinical trials and its subsequent FDA approval is a historic milestone in schizophrenia treatment. He emphasized the importance of CANTAB in enhancing data collection, improving trial accuracy, and accelerating the development of effective treatments for schizophrenia.
The recent approval of Cobenfy and the publication of the analysis in The American Journal of Psychiatry reflect a growing interest in the role of digital technologies in advancing clinical research. Cambridge Cognition's contribution to this progress is evident in its commitment to providing innovative tools for the pharmaceutical industry.
This article is based on information from a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.